G1 Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation
Accretion of discount on available for sale securities
Depreciation and amortization
Loss on disposal of fixed assets
Amortization of debt issuance costs
Loss on extinguishment of debt
Non-cash interest expense
Non-cash equity interest, net
Change in operating assets and liabilities
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued Expenses
Accrued expenses and other liabilities
Deferred revenue

Net cash used in operating activities
Cash flows from investing activities
Purchases of marketable securities
Maturities of marketable securities
Proceeds from disposal of property and equipment
Purchases of property and equipment
Net cash provided by/(used in) investing activities
Cash flows from financing activities
Proceeds from stock options exercised
Proceeds from loan agreement
Payments of debt issuance costs
Proceeds from public offering, net of underwriting fees and commissions
Repayment of debt
Payment of public offering costs
Net cash (used in)/provided by financing activities
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash
Beginning of period
End of period
Supplemental disclosure of cash flow information
Cash paid for interest
Non-cash operating, investing and financing activities
Upfront project costs and other current assets in accounts payable and accrued expenses
Purchases of equipment in accounts payable and accrued expenses
Operating lease liabilities arising from obtaining right-of-use asset
Public offering costs in accounts payable and accrued expenses

Comments